Key Highlights

  • AbCellera completed a $200 million offering of common shares and pre-funded warrants.
  • The third-quarter net loss was $40.8 million.
  • Total cash balances and marketable securities exceeded $790 million at quarter end.
  • Available Liquidity was approximately $900 million after the offering, according to the company's chief executive.

The biotechnology company ended the quarter with more than $790 million in total cash balances and marketable securities. Its chief executive said the company raised $200 million on the strength of recent data and that available liquidity was approximately $900 million.

Net Loss

AbCellera reported a net loss of $40.8 million for the quarter ended September 30, 2026. The company's net loss in the prior-year quarter was higher, according to the comparison the company reported. The company develops antibody medicines and uses its discovery platform to identify and advance candidate therapies for partners and for its own pipeline.

The company's full financial statements set out the components of the net loss.

Offering Completed

The chief executive, quoted in the company's Business results, said the offering followed recent data and that it raised $200 million, bringing available liquidity to approximately $900 million. The offering's terms, including the price per share, are set out in the company's filings.

Cash Balances and Liquidity

The company ended the quarter with over $790 million in total cash balances and marketable securities. The company's total liquidity figure of over $890 million includes additional amounts beyond cash and marketable securities.

Marketable securities are short-term investments that can be converted to cash, and the company's balances are reported at the end of the quarter.

Final Word

Available liquidity of approximately $900 million was cited by the chief executive after the offering.